Innate PharmaIPHA 41 Market Cap is $178.41 Mil as of Jun. 24, 2026. GuruFocus rates IPHA with a GF Score™ of 41/100 and a GF Value™ of $0.16 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,430 Biotechnology companies, Innate Pharma ranks better than 56.43% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Innate Pharma's share price for the quarter that ended in Dec. 2025 was $1.75. Innate Pharma's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 93.70 Mil. Therefore, Innate Pharma's market cap for the quarter that ended in Dec. 2025 was $163.98 Mil.
Innate Pharma's quarterly market cap
increased
from Dec. 2024 ($154.21 Mil) to Jun. 2025 ($167.27 Mil) but then
declined
from Jun. 2025 ($167.27 Mil) to Dec. 2025 ($163.98 Mil).
Innate Pharma's annual market cap
declined
from Dec. 2023 ($226.36 Mil) to Dec. 2024 ($154.21 Mil) but then
increased
from Dec. 2024 ($154.21 Mil) to Dec. 2025 ($163.98 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Innate Pharma's Enterprise Value for Today is $164.82 Mil.
Innate Pharma (NAS:IPHA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Innate Pharma Market Cap Related Terms
Innate Pharma Market Cap Historical Data
* Premium members only.
The historical data trend for Innate Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Innate Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innate Pharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innate Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Innate Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Innate Pharma's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innate Pharma (IPHA) has a Market Cap of $178.41 Mil as of Jun. 24, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Innate Pharma and its competitors. According to the industry distribution chart, Innate Pharma ranks #623 out of 1430 companies in the Biotechnology industry, placing it in the top 43.6%.
Is Innate Pharma's Market Cap too high?
Innate Pharma's current Market Cap is $178.41 Mil. The Biotechnology industry median Market Cap is 117.26. Innate Pharma's value of $178.41 Mil is 52.1% above this industry median. Based on the distribution chart, Innate Pharma ranks #623 out of 1430 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Innate Pharma has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Innate Pharma's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innate Pharma ranks #623 out of 1430 companies for Market Cap. This puts Innate Pharma in the upper half of its industry. The industry median Market Cap is 117.26. Innate Pharma's value of $178.41 Mil is 52.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.26, based on 1,430 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innate Pharma's current Market Cap of $178.41 Mil is 52.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Innate Pharma and its competitors. For the Biotechnology industry, the median Market Cap is 117.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innate Pharma's current Market Cap is $178.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innate Pharma stock overvalued right now?
Based on GuruFocus' analysis, Innate Pharma (IPHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.16, compared to a current price of $1.90 — trading 1087.5% above its estimated fair value. The current Market Cap is $178.41 Mil and 52.1% above the Biotechnology industry median of 117.26. Innate Pharma's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Innate Pharma (IPHA), the current Market Cap is $178.41 Mil as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innate Pharma (IPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued.
The current stock price of $1.90 is trading 1087.5% above its estimated GF Value™ of $0.16.
GuruFocus considers Innate Pharma to be Significantly Overvalued.
Key valuation signals for IPHA:
Market Cap: $178.41 Mil
GF Value™: $0.16 vs. price of $1.90 (1087.5% above fair value)
Industry Position: 52.1% above the Biotechnology median (#623 of 1430)
No single metric tells the full story. See the IPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
41GF Score
Get the complete analysis for IPHA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPHA has been successfully added to your 
